We have studied a total of 36 tumours from 28 patients with germline mutations to the TP53 gene for loss of heterozygosity at TP53 using techniques of both direct sequencing and restriction fragment length polymorphism analysis. All patients were from families conforming to the de®nition of classical Li ± Fraumeni syndrome (LFS) or were Li ± Fraumeni-like (LFL). The data we have obtained show that loss of the wild-type TP53 gene is observed in under half (44%) of all tumours, and that the pattern of LOH at TP53 may be mutation speci®c. LOH has been observed in premalignant as well as invasive tumours. Two tumours (6%) show loss of the mutant allele and retention of the wild-type. To con®rm that TP53 is indeed the target for LOH events on chromosome 17, we have used additional microsatellite repeats to examine patterns of allelic imbalance along the length of chromosome 17. Data from this analysis indicate that TP53 is the target of loss, but reveal some other interesting patterns of allelic imbalance at other loci on chromosome 17.
Introduction
Li ± Fraumeni syndrome (LFS) is an inherited cancer predisposition syndrome characterised by sarcomas in children and young adults, early-onset breast cancer, brain tumours, adrenal cortical carcinoma and leukaemia (Li and Fraumeni, 1969; Li et al., 1988; Birch, 1990; Garber et al., 1991) . Over half of all families conforming to the de®nition of classic LFS and approximately one quarter of those which are Li ± Fraumeni-like (LFL, Birch et al., 1994) carry germline mutations to the TP53 gene (Malkin et al., 1990; Birch et al., 1994; Frebourg et al., 1995; Varley et al., 1997) . Furthermore, a signi®cant proportion of patients with tumours which are typical of those seen in Li ± Fraumeni syndrome have also been shown to carry TP53 germline mutations at an increased frequency Sameshima et al., 1992; Toguchida et al., 1992; Brugieres et al., 1993; Kyritsis et al., 1994; McIntyre et al., 1994; Wagner et al., 1994; Chen et al., 1995; Diller et al., 1995; Li et al., 1995) . TP53 is considered to be a tumour suppressor gene (Hollstein et al., 1991; Levine et al., 1991; Lane, 1992) , and as such some tumours from patients with germline TP53 mutations have been analysed for loss of heterozygosity (LOH). LOH at a particular locus/gene is considered to indicate the presence of a tumour suppressor at that locus (Ponder, 1988) , with the LOH event unmasking the recessive mutation. A number of known tumour suppressor genes such as BRCA1 , RB1 (Cavenee et al., 1983) , BRCA2 (Gudmundsson et al., 1995) , APC (Ichii et al., 1992) and VHL (Tory et al., 1989) have been studied in families in which there is a germline mutation to those genes, and loss of the wild-type allele has been seen at high frequency in the tumours of patients carrying the mutation. All these genes therefore ful®l the criteria expected of tumour suppressor genes, namely obeying Knudson's`two hit' hypothesis (Knudson, 1971) , whereby one defective allele is inherited, and the second is inactivated by loss of part or all of the wild-type chromosome (Ponder, 1988) .
To our knowledge 39 tumours from patients with germline mutations at TP53 have been studied for LOH, with LOH detected in 69% of those tumours (Malkin et al., 1990; Chung et al., 1991; Metzger et al., 1991; Bùrresen et al., 1992; Felix et al., 1992 Felix et al., , 1993 Felix et al., , 1995 Iavarone et al., 1992; Kovar et al., 1992; Prosser et al., 1992; Sameshima et al., 1992; Srivastava et al., 1992; Warneford et al., 1992; Eeles et al., 1993; Scott et al., 1993; Grayson et al., 1994; Gutierrez et al., 1994; Hamelin et al., 1994; Horio et al., 1994; Jolly et al., 1994; Plummer et al., 1994; Chen et al., 1995; Li et al., 1995; Lubbe et al., 1995) . However, there has been no systematic study of LOH in a large series of patients with de®ned TP53 mutations, and in tumour material which has been characterised according to standard criteria by one pathologist. We have identi®ed 19 LFS and LFL families in which there are germline TP53 mutations (Birch et al., 1994; Varley et al., 1997) , and from these we have obtained material from a total of 41 tumours from which we have been able to analyse LOH at TP53 in 36. In addition, we have used microsatellite repeat sequences at various positions along chromosome 17 to determine the extent of the loss, and the nature of the molecular events occurring in those tumours.
Results and Discussion
The results from the analysis of TP53 in tumour DNAs are shown in Table 1 , with a representative example in Figure 1 . The majority of tumour samples were from malignant lesions, but six were from premalignant or benign lesions. DNA from an arachnoid cyst from patient III-4 in family 84, a lipoma from patient IV-2 in family 2252 and a dermato®broma from patient II-1 in family 610 did not show any LOH of the wild-type TP53 allele (Table 1) . These ®ndings were not surprising, particularly as the lesions showing no LOH are not strongly associated with progression. DNA from an adrenal cortical tumour from patient IV-2 in family 117, a benign hyperplastic endometrial lesion from patient III-1 and a ductal carcinoma in situ of the breast from patient IV-1 from family 2252 did, however, show LOH at TP53 (Table 1) . Those premalignant or benign lesions in which LOH was observed are all associated with increased risks of subsequent malignancy. Epithelial hyperplasia with adenomatosis has a small risk (approximately 3%) of subsequent malignancy, and the observation that there was LOH in this lesion may indicate that it was premalignant. The adrenal cortical tumour from patient IV-2 in family 117 was diagnosed on presentation as an adenoma, but on review of sections of the tumour this diagnosis could not be con®rmed. Although the tumour showed some features of an adenoma, there was marked pleomorphism, and it is therefore possible that the tumour was actually a carcinoma rather than an adenoma. Patient IV-2 from family 2252 presented with multifocal comedo DCIS with no evidence of invasion, but this type of DCIS is that most closely associated with risk of recurrence or progression. In the three benign/premalignant tumours in which we have observed LOH at TP53, it would appear that loss of the wild-type allele may be contributing towards the development/progression of the lesion, and could indicate that all three lesions are indeed premalignant/malignant.
Five of the premalignant/benign lesions were examined for allelic imbalance at other loci on This tumour was originally diagnosed as an adrenal cortical adenoma, but on pathology review we were unable to con®rm whether the tumour was an adenoma or a carcinoma chromosome 17. The benign endometrial lesion with adenosis from a patient with a 2 bp deletion within codon 191 showed LOH at TP53 and a closely linked marker D17S1852, and not at any other locus on 17 (Table 1, Figures 2 and 3 ). This result indicates that there has been an interstitial deletion of chromosome 17, removing a region of the short arm of chromosome 17 including the wild-type TP53 allele. A lipoma from a member of the same family showed loss of only the distal 17q marker D17S801 (Figure 2 ). It is not clear whether this ®nding has any relevance. Few studies of LOH have been carried out on lipomas, but they can have quite complex karyotypic alterations (Heim and Mitelman, 1995) . However alterations to chromosome 17 have not been reported. A dermato®broma from a patient with a codon 136 mutation showed LOH at a proximal 17q marker D17S925. The allele that was lost in this benign lesion was dierent to that lost in a lung tumour from the same patient, and may re¯ect random rather than targeted loss. Although there was no LOH at TP53 in the arachnoid cyst from patient III-4 in family 84, there was loss at other chromosome 17 markers. Interestingly there appears to be independent loss at two regions, one possibly involving the entire long arm and the second involving the marker D17S1852. The allele that was lost at this latter locus is dierent to that lost in two malignant lesions from the same patient. Analysis of DNA from the DCIS of patient IV-1 from family 2252 indicated that the LOH observed at TP53 was localised to an interstitial region of the short arm (Figure 3) .
Two tumours showed loss of the mutant TP53 allele, a liposarcoma from patient II-3 in family 83, and an adrenal cortical carcinoma from patient IV-1 in family 85 (Table 1 ). There are a number of possible explanations for this. The ®rst is that the mutation which we have identi®ed in that family has no biological relevance, and we have not identi®ed the true mutation which is associated with the Li ± Fraumeni phenotype. We have no direct evidence that the codon 180 Glu?Lys mutation aects the function of TP53 in family 85, and this mutation has not been reported as either a germline or sporadic mutation (Hollstein et al., 1996) . The mutation would, however, be predicted to perturb the structure of the DNAbinding domain (University of Wisconsin GCG PlotStructure and PepPlot analyses) and cells carrying this mutation are positive in a yeast functional assay (R Camplejohn, personal communication) . In contrast, the mutation in family 83 is one of the commonest mutations seen in either the germline or in sporadic tumours (codon 175, Arg?His), and the functional eects of the mutation are well described (e.g. Dittmer et al., 1993; Ory et al., 1994) . Certainly for this latter family the explanation that there is no biological consequence of the germline mutation is not feasible. The second possible explanation for the loss of the mutant allele is that there is gross genomic instability in these two tumours, and as a result of this the chromosome bearing the mutant allele has been randomly lost. There appears to be almost complete loss of the mutant TP53 allele in both tumours indicating that the majority of tumour cells must have lost the mutant TP53 allele; such an eect would be predicted to have taken place relatively early in the development of the tumour. It is possible that the presence of mutant p53 protein is only necessary for the initial stages in the development of a tumour, and its continued presence is not obligatory. In experimental systems there is, however, considerable pressure towards loss of wild-type p53 function and maintenance of the mutant p53 expression. A third explanation is that somatic mutation to the wild-type allele has occurred, and this allele has been retained in preference to the germline mutation. We have insucient material from these tumours to sequence the retained allele, and therefore cannot rule this out. A fourth explanation is that there is another gene on chromosome 17 which has the characteristics of a tumour suppressor, and which is the target for the loss event detected at TP53. Should a somatic mutation occur within one allele of such a gene on the chromosome which carries the wild-type TP53 allele, the selective pressure on a cell which has retained the mutation at the second tumour suppressor might be stronger than the selective pressure on cells retaining the mutant TP53. We have attempted to address these possibilities by looking at retention or loss of other highly polymorphic markers along both arms of chromosome 17 (Figure 3 ). Unfortunately we were only able to amplify one microsatellite marker from patient II-3 in family 83, which was uninformative. In the second tumour (patient IV-1 in family 85) there appeared to be loss at all other informative chromosome 17 markers studied. We have not therefore been able to con®rm whether TP53 is the target of LOH seen in these two tumours. Interestingly there appears to be another report in the literature of loss of the mutant allele (Eeles et al., 1993) , rasining the possibility that the event is not uncommon in Li ± Fraumeni tumours. Patient III-6 (family 117) presented with a gastric adenocarcinoma aged 35 and carried a germline mutation at codon 175 (Arg?His). There was no LOH at TP53 in this tumour. To our knowledge there are only three other reports of examination of gastric tumours for LOH at TP53 in carriers of germline mutations, and all three showed retention of the wildtype allele (Scott et al., 1993; Horio et al., 1994) . The study of four tumours is insucient to be able to make general conclusions, but the retention of wild-type TP53 in all four is interesting.
In contrast, of seven breast tumours in the present study, only one retained the wild-type allele. In addition, one DCIS of the breast also showed LOH at TP53. Of the six literature reports of breast tumours in patients with germline TP53 mutations, four showed loss of the wild-type allele (Malkin et al., 1990 ; Bùrresen et al., 1992; Prosser et al., 1992; Srivastava et al., 1992; Warneford et al., 1992; Eeles et al., 1993) . Loss of the wild-type allele in breast tumours in patients with germline TP53 mutations therefore appears to be frequent. There is evidence for a second tumour suppressor sequence mapping to the short arm of chromosome 17, distal to TP53 at 17p13.3 (Mackay et al., 1988; Coles et al., 1990; Cornelis et al., 1994; Stack et al., 1995) , and we considered whether this second gene could be the target of the LOH observed at TP53. We used a marker known to map very close to this candidate tumour suppressor, D17S695 (Stack et al., 1995) , and examined LOH at 17p13.3. Clearly TP53 and not this distal gene is the target for LOH, with retention of heterozygosity at D17S695 in threequarters breast tumours informative at both loci (Figure 3) , with a fourth tumour showing apparent gain of all other informative markers on 17 indicating reduplication of one copy of chromosome 17.
One of the most striking ®ndings is that in tumours from patients with codon 248 germline mutations there is no LOH in any tumour with the exception of breast tumours. Thirteen tumours from such patients were studied (Table 1) , including essentially all the types characteristic of Li ± Fraumeni syndrome. In two cases we obtained material from both a breast tumour and another tumour from the same patient (family 84, patient III-4 and family 266, patient II-2, Table 1 ). In both these individuals we observed LOH in the breast tumour, but not in the other tumours. If we exclude patients with codon 248 mutations from our analysis we ®nd LOH at TP53 in around 60% of tumours, which is closer to the ®gure obtained from literature reports, where only one tumour with a codon 248 mutation has been reported (Scott et al., 1993) . This latter tumour did not show LOH, although the authors discussed the possibility that the presence of large numbers of normal cells in the biopsy could have masked LOH.
The most obvious explanation for the observation that there is retention of heterozygosity in tumours from patients with codon 248 mutations is that they are dominant gain-of-function mutations (Dittmer et al., 1993) , and therefore there is little selective pressure for loss of the wild-type allele. From published studies in which various mutant p53 proteins have been examined for a variety of functions, there is diverse evidence concerning codon 248 mutant p53. For example it retains wild-type conformation and does not bind hsp70, and it fails to transactivate target genes (Ory et al., 1994) . Codon 248 mutant p53 may or may not confer a tumorigenic phenotype on cells depending on the recipient cell line tested (Dittmer et al., 1993) . Antisense experiments showed that a codon 248 mutant retained signi®cant tumour suppressor activity (Mukhopadhyay and Roth, 1993) . Arginine 248 is a key residue involved in direct contact between p53 and DNA (Cho et al., 1994) , and mutations to this residue would be expected to perturb interactions between p53 and its target sequences. Data from our own laboratory indicate that p53 which is mutant at codon 248 is defective in permanent G 1 arrest (Williams et al., 1996) . This aberrant feature of codon 248 mutant p53 is the most striking dierence from the wild-type protein, and is proposed to contribute towards the susceptibility to tumours in patients with germline TP53 mutations. There is, however, no particular feature of codon 248 mutants which set them apart from other mutants and which could explain the retention of heterozygosity that we see in tumours from LFS patients.
In all tumours where we failed to detect LOH we cannot rule out the possibility that a second somatic mutation has occurred in the wild-type allele. The limited amount of material available from many of these tumours precludes a comprehensive sequence analysis of the entire gene. It seems unlikely, however, that second mutations account for all the tumours which do not show LOH.
Data obtained by examining allele imbalance at loci along both chromosome 17 arms con®rm that the target for LOH in patients with germline TP53 mutations is indeed TP53, and not other candidate tumour suppressors on chromosome 17. This result is unsurprising, but has not been demonstrated previously. In two cases we have been able to analyse the karyotype of the tumour cells, and in both cases these data supported the molecular analysis reported in the present study (III-6 in family 7003, see Varley et al. (1996) and III-1 in family 1502, ELD Mitchell, unpublished data). However in some tumours, including all those with codon 248 mutations, there is LOH at THRA1, which is a marker closely linked to BRCA1. The tumour types in which LOH at THRA1 is seen are diverse and include breast tumours, sarcomas, and adrenal cortical carcinomas. The signi®cance of this ®nding is unclear. It is interesting to note that in breast tumours there is no LOH at the distal 17p marker which maps close to a candidate tumour suppressor gene which is frequently lost in breast tumours (Coles et al., 1990; Stack et al., 1995) . However Cornelis et al. (1994) have observed loss at distal 17p predominantly in sporadic breast tumours where there is no mutation to TP53.
In no case did it appear that a tumour was de®nitely hemizygous at all loci on chromosome 17. Two tumours, however, (IV-1 in family 85 and II-3, family 83) showed loss at all informative loci, although in the case of the latter patient only two loci could be analysed. Both these tumours showed loss of the mutant TP53 gene, as discussed above. Five tumours appear to have a reduction in intensity of one allele with concomitant gain of the other at all informative loci; four of these show LOH at TP53 (see Figures 2 and 3) although gain of the retained mutant allele was not assessed. These data are compatible with loss of the wild-type allele by loss of an entire chromosome followed by reduplication of the chromosome carrying the mutant TP53 allele. The residual signal from one allele could be explained by the stromal component within the tumour section. The remainder of the tumours showed patterns of loss compatible with interstitial loss of either chromosome arm, or loss of an entire chromosome arm. All these observations for the mechanisms of loss of the wildtype allele of a tumour suppressor have previously been noted in other inherited cancer syndromes (Cavenee et al., 1983; Zhu et al., 1992) . However, the relative frequency of loss by mechanisms which result in hemizygosity or reduction to homozygosity of only part of the chromosome (e.g. mitotic recombination) is higher in this series of tumours than that reported for other tumour types (Cavenee et al., 1983; Cavenee, 1990) . The signi®cance of this is not clear at the moment, but this observation coupled with the ®nding that there is loss of sequences along the length of chromosome 17 in many tumour types, including benign/premalignant lesions, may re¯ect an increased overall genomic instability in lesions from patients with germline TP53 mutations.
Materials and methods
Details of the patients and tumours are given in Table 1 . Pedigree and family numbers are the same as those used by Varley et al. (1997) . The majority of tumour samples were obtained as formalin-®xed, paran-embedded tumour blocks. Sections were cut from these blocks, and were stained with haematoxylin and eosin for review to con®rm the tumour type and the percentage of tumour cells within the section. In addition, appropriate immunohistochemical staining was undertaken to de®ne the precise histological tumour type (Kelsey et al., manuscript in preparation). One or more adjacent 5 ± 25 mM sections were then cut and transferred into clean sterile plastic vials to be processed for DNA extraction. In several cases blocks of normal material were also obtained, these were similarly assessed and processed. DNA was extracted from the sections using previously published procedures (Birch et al., 1994) .
In all cases studied, a germline TP53 mutation had been identi®ed and con®rmed by direct sequencing (Varley et al., 1997) . Loss of heterozygosity at TP53 was assessed by direct DNA sequence analysis of tumour DNA for the presence or absence of the wild-type allele (see Figure 1) . In all cases a normal control (constitutional DNA from the same person or from an aected or unaected carrier within the same family) was analysed on the same gel using the same chemistry. Sequencing was carried out using either dye terminator or dye primer chemistries and an ABI model 373 or 377 automated DNA sequencer. In many cases it was possible to use a diagnostic restriction digest (Table 1) to con®rm the presence of the mutation and to assess LOH. Wherever possible this procedure was carried out to con®rm the results of the direct sequencing, using samples which had been prepared in separate PCR reactions.
For 23 of the tumours examined for LOH at TP53, we also had constitutional DNA from either peripheral blood lymphocytes or from paran-embedded blocks. Allelic imbalance at ®ve microsatellite repeat sequences on chromosome 17 was assessed using methods essentially as described in Hoggard et al. (1995) , except that the oligonucleotide primers were labelled using [ (Gerken et al., 1995) mapping to 17p13.3 (Stack et al., 1995) ; D17S1852, mapping 7 centimorgans (cM) proximal to TP53 (Gyapay et al., 1994) ; D17S925 (Gyapay et al., 1994) , mapping in the region of 17q11; THRA1 (Bowcock et al., 1993) mapping to 17q21 in the region of the familial breast cancer gene BRCA1; and D17S801 (Gyapay et al., 1994) mapping near the telomere of 17q. The chromosomal location of D17S925 was previously not known. The verify that it did indeed map to 17q, a yeast arti®cial chromosome (YAC) was isolated corresponding to D17S925. The YAC was mapped by hybridising to normal human chromosomes using standard procedures, and a signal was obtained at 17q11 (GRM White and LA James, personal communication). Loss of heterozygosity at all loci was deduced when the intensity of one band in the tumour DNA was reduced in the tumour DNA sample compared to the normal. Apparent gain was scored when one band in the tumour DNA appeared to be at an increased intensity with respect to the other when compared with normal DNA (see Figure 2) . In all cases where apparent gain was scored, there appeared to be a concomitant reduction in signal from the other allele.
